Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nab-paclitaxel · 1 trial · 1 indication
Determine the maximum tolerated dose (MTD) level and designate the recommended dose level for phase II.
Number and severity of treatment related adverse events (AEs) that occur or worsen after the first dose of study treatment
Determine the 8.5 month overall survival of treated patients
| Arm | Type | Description |
|---|---|---|
| Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Gemcitabine | BIOLOGICAL | Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles. |
| Nab-paclitaxel | BIOLOGICAL | Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles. |
| ALT-803 | BIOLOGICAL | Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles. |
DISEASE CHARACTERISTICS: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of pancreatic cancer. * For dose escalation phase (Phase Ib) distant metastatic disease or unresectable disease and not a candidate for down staging to resection. * For expansion phase (Phase II...
Top 20 of 67 competitors
Nab-paclitaxel is being studied for use in advanced pancreatic cancer. It is an investigational drug currently in Phase 1 clinical development. In the completed trial, it was administered in conjunction with gemcitabine and ALT-803 to patients with advanced pancreatic cancer.
Nab-paclitaxel targets tubulin proteins, specifically TUBB4B, TUBB1, TUBA3C, TUBA4A, TUBB3, and TUBA1A. It acts as an inhibitor of these molecular targets, which are involved in microtubule dynamics within cells.
Nab-paclitaxel is being developed by ImmunityBio, Inc., a company traded on the stock exchange under the ticker symbol IBRX. The company is conducting clinical research to evaluate the drug's potential in treating advanced pancreatic cancer.
Nab-paclitaxel is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 8 patients with advanced pancreatic cancer.
Nab-paclitaxel has been studied in one clinical trial with the identifier NCT02559674, titled 'QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel'. This Phase 1 trial was completed in the United States and enrolled 8 patients.
No, Nab-paclitaxel is not the same as ALT-803. In the clinical trial NCT02559674, Nab-paclitaxel was administered in conjunction with gemcitabine and ALT-803, indicating they are distinct agents used together in the treatment regimen for advanced pancreatic cancer.